HDAC9 and neoplasm: Nonetheless, these general HDAC inhibitors are poorly tolerated at the relatively high doses required to block tumor growth, and thus there is great interest in developing isoform-selective HDAC inhibitors with the goal of improving tolerability and efficacy.